论文部分内容阅读
药物基因组学公司Foundation Medicine正在提供一项新测试,帮助肿瘤学家根据病人肿瘤细胞的遗传情况有针对性地选择药物,个性化癌症治疗得以实现了吗?迈克尔·佩利尼(Michael Pellini)启动了他的电脑,并打开一份唾液腺肿瘤病人的报告。病人已经做了手术,但癌细胞又复发了。病人的一份活体切片被送到佩利尼经营的Foundation Medicine公司,以进行详细的DNA研究。Foundation Medicine检测了约200个已知的与癌症相关的基因,并发现了3个突变。
Foundation Medicine, a pharmacogenomics company, is offering a new test to help oncologists choose drugs specifically for the genetic condition of their tumor cells and to personalize cancer treatment? Michael Pellini Launches Took his computer and opened a report on patients with salivary gland tumors. The patient has undergone surgery, but the cancer has recurred. A biopsy of the patient was sent to Foundation Medicine, run by Perlini, for detailed DNA research. Foundation Medicine tested about 200 known cancer-associated genes and found 3 mutations.